血浆miR-145-5p水平与癌症相关血栓风险:HUNT研究结果
基于HUNT3队列(N=50 807)的病例队列研究,测量血浆miR-145-5p水平,随访9年共455例VTE(其中95例为CAT),随机抽样1740名亚队列参与者。多变量加权Cox回归显示,miR-145-5p每升高1个标准差,CAT风险HR为0.70(95%CI 0.52-0.96),非CAT风险HR为0.81(95%CI 0.72-0.91)。结论提示高血浆miR-145-5p水平与较低的CAT和非CAT风险相关,可能作为CAT风险生物标志物。
要点
- 血浆miR-145-5p每升高1个标准差,癌症相关静脉血栓栓塞风险HR为0.70(95%CI 0.52-0.96)。
- 血浆miR-145-5p每升高1个标准差,非癌症相关静脉血栓栓塞风险HR为0.81(95%CI 0.72-0.91)。
- 最高四分位组相比最低四分位组,CAT风险HR为0.55(95%CI 0.25-1.20),非CAT风险HR为0.48(95%CI 0.33-0.69)。
核心结论
- 高血浆miR-145-5p水平与较低的癌症相关静脉血栓栓塞和非癌症相关静脉血栓栓塞风险相关。
- miR-145-5p有潜力作为癌症相关静脉血栓栓塞的风险生物标志物。
研究设计与样本
- 病例队列研究,血浆miR-145-5p水平在源自Trøndelag健康研究(HUNT3;N=50 807)的病例队列中测量。
- 研究纳入随访9年间发生的455例VTE(其中95例CAT)和1740名随机抽样的年龄加权亚队列参与者。
- VTE分类为CAT的条件是发生在癌症诊断前1年内或诊断后2年内。
- 使用加权Cox回归估计CAT和非CAT的多变量校正风险比(HR),癌症作为时变协变量建模。
主要发现
- miR-145-5p水平升高与较低的CAT风险相关(每1个标准差HR,0.70;95%CI,0.52-0.96)。
- miR-145-5p水平升高与较低的非CAT风险相关(HR,0.81;95%CI,0.72-0.91)。
- 最高miR-145-5p四分位组相比最低四分位组,CAT风险HR为0.55(95%CI,0.25-1.20),非CAT风险HR为0.48(95%CI,0.33-0.69)。
临床怎么用
- 血浆miR-145-5p水平可能辅助识别癌症相关静脉血栓栓塞高风险患者。
- 需进一步研究验证miR-145-5p作为CAT风险生物标志物的临床效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The incidence of cancer-associated venous thromboembolism (CAT) has risen in recent decades, underscoring the need for novel risk biomarkers and mechanistic insights. MicroRNAs (miRNAs) have emerged as promising biomarkers for various diseases, with elevated miRNA-145-5p (miR-145-5p) levels linked to reduced venous thromboembolism (VTE) risk. We aimed to investigate the association between plasma miR-145-5p levels and risk of future VTE related to (CAT) and unrelated to cancer (non-CAT). METHODS: Plasma miR-145-5p levels were measured in a case cohort derived from the Trøndelag Health Study (HUNT3; N = 50 807). The study included 455 VTEs (95 CATs), occurring during 9 years of follow-up, and 1740 randomly sampled age-weighted subcohort participants. VTEs were classified as CAT if they occurred within 1 year before or 2 years after a cancer diagnosis. Multivariable adjusted hazard ratios (HRs) for CAT and non-CAT were estimated using weighted Cox regression, with cancer modeled as a time-varying covariate. RESULTS: Increasing miR-145-5p levels were associated with lower risk of CAT (HR per 1 SD, 0.70; 95% CI, 0.52-0.96) and non-CAT (HR, 0.81; 95% CI, 0.72-0.91). Individuals in the highest miR-145-5p quartile had lower risk of both CAT (HR, 0.55; 95% CI, 0.25-1.20) and non-CAT (HR, 0.48; 95% CI, 0.33-0.69) than those in the lowest quartile. CONCLUSIONS: High plasma miR-145-5p levels were associated with lower risk of CAT and non-CAT, suggesting that miR-145-5p has the potential to serve as a risk biomarker for CAT.
引用
- Antoun C, Oto J, Herranz R, et al. Plasma miR-145-5p levels and risk of cancer-associated thrombosis-results from the HUNT study. J Thromb Haemost. 2026. PMID: 41580146. doi:10.1016/j.jtha.2025.12.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。